iCliniq Logo
HomeAnswersGeneral Practitionersystemic lupus erythematosus

What are the newer options that can manage SLE and ITP?

This Premium Q&A, reviewed and published, features a real conversation between an iCliniq user and a physician.

Patient's Query

Hello doctor,

I am a 35-year-old woman diagnosed with SLE four years ago, and I have also been dealing with chronic immune thrombocytopenia (ITP) for the past two years. My platelet counts remain persistently low, ranging between 25,000 and 40,000/μL, despite being on low-dose Prednisone and Hydroxychloroquine.

Recently, I have noticed increased bruising on my arms and legs, occasional gum bleeding, and heavy periods. My latest CBC showed a platelet count of 22,000/μL, hemoglobin at 10.2 g/dL, and a normal WBC count.

My ANA remains strongly positive at 1:1280 (homogeneous), anti-dsDNA is elevated at 135 IU/mL, and my complement levels are low (C3 at 60 mg/dL, C4 at 8 mg/dL). A bone marrow biopsy done previously ruled out marrow failure.

My rheumatologist is now considering adding a second-line treatment, such as Rituximab or a thrombopoietin receptor agonist. I am concerned about the bleeding risks and the side effects of stronger immunosuppressants. How can I balance treatment for both SLE and ITP, and are there any newer, safer options that target both conditions? Should I be monitoring any other markers or adjusting my activity level to reduce the risk of bleeding?

Please help.

Hello,

Welcome to icliniq.com.

I understand your concern.

According to your medical history and your concern regarding the simultaneous treatment of SLE (systemic lupus erythematosus) and ITP (immune thrombocytopenic purpura), your platelet count is continuing to decrease despite treatment with low-dose Prednisone and Hydroxychloroquine. You are now experiencing bruising on your extremities, gum bleeding, and heavy menstrual bleeding. All of which are symptoms caused by low platelet levels.

Your latest reports show:

  • Platelet count is 22,000 per microliter, which is very low.

  • Hemoglobin (Hb) is 10.2, which is slightly low.

  • ANA (antinuclear antibody) and anti-ds-DNA (anti-double-stranded DNA antibody test) are positive.

  • Complements C3 (component 3) and C4 (component 4) are low.

Your current medicine is not sufficient because you develop bleeding and bruises.

SLE is commonly treated with NSAIDs (nonsteroidal anti-inflammatory drugs), corticosteroids, immunosuppressants, and antimalarials.

As of now, you mainly develop features of thrombocytopenia (low platelets), which is because your platelets are broken down by the immune system.

To prevent the breakdown of platelets, you now need immunosuppressants, which will help in increasing the platelet count. Immunosuppressants, such as Rituximab, Belimumab, Cyclophosphamide, Methotrexate, and Azathioprine, will help you.

I think this is one of the most suitable options for you at this point in time.

SLE and ITP are both linked, so you do not need to take separate treatments for both. Do not worry, and add immunosuppressants to the treatment.

I hope this has helped you.

Please feel free to reach out to me again if you have further queries.

Thank you.

Answered byDr. Nitesh Meena

Medically reviewed byiCliniq medical review team

Published At October 4, 2025
Reviewed AtFebruary 27, 2026

Same symptoms don't mean you have the same problem. Consult a doctor now!

Listen to related tracks in our music library

Ask your health query to a doctor online

*guaranteed answer within 4 hours

Disclaimer: No content published on this website is intended to be a substitute for professional medical diagnosis, advice or treatment by a trained physician. Seek advice from your physician or other qualified healthcare providers with questions you may have regarding your symptoms and medical condition for a complete medical diagnosis. Do not delay or disregard seeking professional medical advice because of something you have read on this website. Read our Editorial Process to know how we create content for health articles and queries.